| Literature DB >> 20159475 |
Abstract
Craniomaxillofacial surgery has many indications for bone regeneration and augmentation, ranging from socket preservation to reconstruction of large skeletal defects. The discovery of bone morphogenetic proteins (BMPs) as osteoinductive agents and the subsequent development of commercially available recombinant forms of BMPs have offered the potential to replace traditional grafting techniques with de novo bone formation. Extensive preclinical and clinical research has focused on establishing the safety and efficacy of using recombinant BMPs to regenerate bone in the facial skeleton. This article reviews the development and current scientific basis behind the use of these new biologics. Copyright (c) 2010 Elsevier Inc. All rights reserved.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20159475 DOI: 10.1016/j.coms.2009.10.007
Source DB: PubMed Journal: Oral Maxillofac Surg Clin North Am ISSN: 1042-3699 Impact factor: 2.802